Clinical and prognostic significance of prokineticin 1 in human gliomas.

The objective of this study was to explore the expression and the clinical and prognostic significance of prokineticin 1 (PROK1) in human gliomas. The expression of PROK1 in 60 patients with glioma and in eight control cases (patients with traumatic brain injury) by immunohistochemistry (IHC). The associations between the differences in expression and pathology grades were analyzed statistically. The positive rates of PROK1 expression in normal brain and glioma tissue were 25.0% (2/8) and 93.3% (56/60), respectively. PROK1 expression in glioma tissue was higher than that in normal tissue (<0.05). The positive rates of PROK1 expression in low-grade gliomas (LGGs, grades I and II) and high-grade gliomas (HGGs, grades III and IV) were 66.7% (8/12) and 100% (48/48), respectively, the positive rates in HGG were higher than those in LGG (<0.01). PROK1 is an angiogenic growth factor that is related with metastatic ability of tumor, we also correlated PROK1 expression with NFAT expression. Expression of PROK1correlated significantly with expression of NFAT (r=0.524, <0.01), but not with patient sex and age. Glioma patients with higher expressing PROK1 had a significantly shorter progression-free survival time, increasing levels of PROK1 expression significantly correlated with reduced survival times when all patients with glioma were considered (<0.01). These results suggested that PROK1 positivity and protein expression levels are of significant clinical and prognostic value in human gliomas, which significantly correlates with the survival in gliomas, PROK1 may regulate the progression of glioma via the NFAT pathway.